瑞替加滨 (Chinese Wikipedia)

Analysis of information sources in references of the Wikipedia article "瑞替加滨" in Chinese language version.

refsWebsite

Global rank Chinese rank

12nih.gov

4^th place

5^th place

12doi.org

2^nd place

23^rd place

10web.archive.org

1^st place

4semanticscholar.org

11^th place

332^nd place

2fda.gov

447^th place

581^st place

2medscape.com

719^th place

889^th place

2drugs.com

399^th place

208^th place

1archive.org

6^th place

4^th place

1gsksource.com

low place

1epilepsysociety.org.uk

low place

1medicines.org.uk

3,823^rd place

3,456^th place

1gpo.gov

1,360^th place

1,262^nd place

archive.org (Global: 6^th place; Chinese: 4^th place)

Ferron GM, Paul J, Fruncillo R, Richards L, Knebel N, Getsy J, Troy S. Multiple-dose, linear, dose-proportional pharmacokinetics of retigabine in healthy volunteers. Journal of Clinical Pharmacology. February 2002, 42 (2): 175–182. PMID 11831540. S2CID 5568963. doi:10.1177/00912700222011210.

doi.org (Global: 2^nd place; Chinese: 23^rd place)

Ferron GM, Paul J, Fruncillo R, Richards L, Knebel N, Getsy J, Troy S. Multiple-dose, linear, dose-proportional pharmacokinetics of retigabine in healthy volunteers. Journal of Clinical Pharmacology. February 2002, 42 (2): 175–182. PMID 11831540. S2CID 5568963. doi:10.1177/00912700222011210.
Rundfeldt C. The new anticonvulsant retigabine (D-23129) acts as an opener of K+ channels in neuronal cells. European Journal of Pharmacology. October 1997, 336 (2–3): 243–249. PMID 9384239. doi:10.1016/S0014-2999(97)01249-1.
Main MJ, Cryan JE, Dupere JR, Cox B, Clare JJ, Burbidge SA. Modulation of KCNQ2/3 potassium channels by the novel anticonvulsant retigabine. Molecular Pharmacology. August 2000, 58 (2): 253–262. PMID 10908292. S2CID 11112809. doi:10.1124/mol.58.2.253.
Rogawski MA, Bazil CW. New molecular targets for antiepileptic drugs: alpha(2)delta, SV2A, and K(v)7/KCNQ/M potassium channels. Current Neurology and Neuroscience Reports. July 2008, 8 (4): 345–352. PMC 2587091 . PMID 18590620. doi:10.1007/s11910-008-0053-7.
Plosker GL, Scott LJ. Retigabine: in partial seizures. CNS Drugs. 2006, 20 (7): 601–8; discussion 609–10. PMID 16800718. doi:10.2165/00023210-200620070-00005.
Porter RJ, Partiot A, Sachdeo R, Nohria V, Alves WM. Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures. Neurology. April 2007, 68 (15): 1197–1204. PMID 17420403. S2CID 24574886. doi:10.1212/01.wnl.0000259034.45049.00.
Ben-Menachem E. Retigabine: has the orphan found a home?. Epilepsy Currents. 2007, 7 (6): 153–154. PMC 2096728 . PMID 18049722. doi:10.1111/j.1535-7511.2007.00209.x.
Luszczki JJ. Third-generation antiepileptic drugs: mechanisms of action, pharmacokinetics and interactions. Pharmacological Reports. 2009, 61 (2): 197–216. PMID 19443931. S2CID 72918370. doi:10.1016/s1734-1140(09)70024-6.
Corbin-Leftwich A, Mossadeq SM, Ha J, Ruchala I, Le AH, Villalba-Galea CA. Retigabine holds KV7 channels open and stabilizes the resting potential. The Journal of General Physiology. March 2016, 147 (3): 229–241. PMC 4772374 . PMID 26880756. doi:10.1085/jgp.201511517.
Villalba-Galea CA. Modulation of K_V7 Channel Deactivation by PI(4,5)P₂. Frontiers in Pharmacology. 2020-06-19, 11: 895. PMC 7318307 . PMID 32636742. doi:10.3389/fphar.2020.00895 .
Brown DA, Passmore GM. Neural KCNQ (Kv7) channels. British Journal of Pharmacology. April 2009, 156 (8): 1185–1195. PMC 2697739 . PMID 19298256. doi:10.1111/j.1476-5381.2009.00111.x.
Rogawski MA. Diverse mechanisms of antiepileptic drugs in the development pipeline. Epilepsy Research. June 2006, 69 (3): 273–294. PMC 1562526 . PMID 16621450. doi:10.1016/j.eplepsyres.2006.02.004.

drugs.com (Global: 399^th place; Chinese: 208^th place)

Valeant Pharmaceuticals Announces Preliminary Results From Its Phase IIa Retigabine Study for the Treatment of Postherpetic Neuralgia (PHN) (新闻稿). PRNewswire. 2009-08-24 [2011-06-13]. （原始内容存档于2016-09-21）.
Retigabine NDA accepted for filing (新闻稿). PRNewswire. 2009-12-30 [2010-07-19]. （原始内容存档于2023-10-10）.

epilepsysociety.org.uk (Global: low place; Chinese: low place)

Epilepsy drug Trobalt (retigabine) to be discontinued. epilepsysociety.org.uk. 14 September 2016 [2023-11-07]. （原始内容存档于2023-10-10）.

fda.gov (Global: 447^th place; Chinese: 581^st place)

Potiga (Ezogabine): Drug Safety Communication. Food and Drug Administration. [2023-11-07]. （原始内容存档于2017-04-06）.
[No authors listed]. August 11, 2010: Peripheral and Central Nervous System Drugs Advisory Committee Meeting Announcement. U.S. Food and Drug Administration. 2010-06-25 [2010-07-19]. （原始内容存档于2017-07-22）.

gpo.gov (Global: 1,360^th place; Chinese: 1,262^nd place)

U.S. Drug Enforcement Administration. Schedules of Controlled Substances: Placement of Ezogabine Into Schedule V (PDF). Federal Register. 15 December 2011, 76 (241) [2023-11-07]. （原始内容存档 (PDF)于2017-06-16）.

gsksource.com (Global: low place; Chinese: low place)

POTIGA (ezogabine) Tablets, CV. Full Prescribing Information (PDF). GlaxoSmithKline and Valeant Pharmaceuticals. [4 June 2014]. （原始内容存档 (PDF)于2016-03-21）.

medicines.org.uk (Global: 3,823^rd place; Chinese: 3,456^th place)

Trobalt – Summary of Product Characteristics (SPC). electronic Medicines Compendium. 2011-05-05 [2011-06-13]. （原始内容存档于2017-08-06）.

medscape.com (Global: 719^th place; Chinese: 889^th place)

Hitt E. FDA approves ezogabine for seizures in adults. Medscape. 2011-06-13 [2011-06-13]. （原始内容存档于2023-10-10）.
Lowry F. Epilepsy drug exogabine gets green light from FDA Advisory Panel. Medscape. 2010-08-12 [2010-08-13]. （原始内容存档于2023-10-10）.

nih.gov (Global: 4^th place; Chinese: 5^th place)

ncbi.nlm.nih.gov

Ferron GM, Paul J, Fruncillo R, Richards L, Knebel N, Getsy J, Troy S. Multiple-dose, linear, dose-proportional pharmacokinetics of retigabine in healthy volunteers. Journal of Clinical Pharmacology. February 2002, 42 (2): 175–182. PMID 11831540. S2CID 5568963. doi:10.1177/00912700222011210.
Rundfeldt C. The new anticonvulsant retigabine (D-23129) acts as an opener of K+ channels in neuronal cells. European Journal of Pharmacology. October 1997, 336 (2–3): 243–249. PMID 9384239. doi:10.1016/S0014-2999(97)01249-1.
Main MJ, Cryan JE, Dupere JR, Cox B, Clare JJ, Burbidge SA. Modulation of KCNQ2/3 potassium channels by the novel anticonvulsant retigabine. Molecular Pharmacology. August 2000, 58 (2): 253–262. PMID 10908292. S2CID 11112809. doi:10.1124/mol.58.2.253.
Rogawski MA, Bazil CW. New molecular targets for antiepileptic drugs: alpha(2)delta, SV2A, and K(v)7/KCNQ/M potassium channels. Current Neurology and Neuroscience Reports. July 2008, 8 (4): 345–352. PMC 2587091 . PMID 18590620. doi:10.1007/s11910-008-0053-7.
Plosker GL, Scott LJ. Retigabine: in partial seizures. CNS Drugs. 2006, 20 (7): 601–8; discussion 609–10. PMID 16800718. doi:10.2165/00023210-200620070-00005.
Porter RJ, Partiot A, Sachdeo R, Nohria V, Alves WM. Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures. Neurology. April 2007, 68 (15): 1197–1204. PMID 17420403. S2CID 24574886. doi:10.1212/01.wnl.0000259034.45049.00.
Ben-Menachem E. Retigabine: has the orphan found a home?. Epilepsy Currents. 2007, 7 (6): 153–154. PMC 2096728 . PMID 18049722. doi:10.1111/j.1535-7511.2007.00209.x.
Luszczki JJ. Third-generation antiepileptic drugs: mechanisms of action, pharmacokinetics and interactions. Pharmacological Reports. 2009, 61 (2): 197–216. PMID 19443931. S2CID 72918370. doi:10.1016/s1734-1140(09)70024-6.
Corbin-Leftwich A, Mossadeq SM, Ha J, Ruchala I, Le AH, Villalba-Galea CA. Retigabine holds KV7 channels open and stabilizes the resting potential. The Journal of General Physiology. March 2016, 147 (3): 229–241. PMC 4772374 . PMID 26880756. doi:10.1085/jgp.201511517.
Villalba-Galea CA. Modulation of K_V7 Channel Deactivation by PI(4,5)P₂. Frontiers in Pharmacology. 2020-06-19, 11: 895. PMC 7318307 . PMID 32636742. doi:10.3389/fphar.2020.00895 .
Brown DA, Passmore GM. Neural KCNQ (Kv7) channels. British Journal of Pharmacology. April 2009, 156 (8): 1185–1195. PMC 2697739 . PMID 19298256. doi:10.1111/j.1476-5381.2009.00111.x.
Rogawski MA. Diverse mechanisms of antiepileptic drugs in the development pipeline. Epilepsy Research. June 2006, 69 (3): 273–294. PMC 1562526 . PMID 16621450. doi:10.1016/j.eplepsyres.2006.02.004.

semanticscholar.org (Global: 11^th place; Chinese: 332^nd place)

api.semanticscholar.org

Ferron GM, Paul J, Fruncillo R, Richards L, Knebel N, Getsy J, Troy S. Multiple-dose, linear, dose-proportional pharmacokinetics of retigabine in healthy volunteers. Journal of Clinical Pharmacology. February 2002, 42 (2): 175–182. PMID 11831540. S2CID 5568963. doi:10.1177/00912700222011210.
Main MJ, Cryan JE, Dupere JR, Cox B, Clare JJ, Burbidge SA. Modulation of KCNQ2/3 potassium channels by the novel anticonvulsant retigabine. Molecular Pharmacology. August 2000, 58 (2): 253–262. PMID 10908292. S2CID 11112809. doi:10.1124/mol.58.2.253.
Porter RJ, Partiot A, Sachdeo R, Nohria V, Alves WM. Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures. Neurology. April 2007, 68 (15): 1197–1204. PMID 17420403. S2CID 24574886. doi:10.1212/01.wnl.0000259034.45049.00.
Luszczki JJ. Third-generation antiepileptic drugs: mechanisms of action, pharmacokinetics and interactions. Pharmacological Reports. 2009, 61 (2): 197–216. PMID 19443931. S2CID 72918370. doi:10.1016/s1734-1140(09)70024-6.

web.archive.org (Global: 1^st place; Chinese: 1^st place)

POTIGA (ezogabine) Tablets, CV. Full Prescribing Information (PDF). GlaxoSmithKline and Valeant Pharmaceuticals. [4 June 2014]. （原始内容存档 (PDF)于2016-03-21）.
Epilepsy drug Trobalt (retigabine) to be discontinued. epilepsysociety.org.uk. 14 September 2016 [2023-11-07]. （原始内容存档于2023-10-10）.
Potiga (Ezogabine): Drug Safety Communication. Food and Drug Administration. [2023-11-07]. （原始内容存档于2017-04-06）.
Hitt E. FDA approves ezogabine for seizures in adults. Medscape. 2011-06-13 [2011-06-13]. （原始内容存档于2023-10-10）.
Trobalt – Summary of Product Characteristics (SPC). electronic Medicines Compendium. 2011-05-05 [2011-06-13]. （原始内容存档于2017-08-06）.
Valeant Pharmaceuticals Announces Preliminary Results From Its Phase IIa Retigabine Study for the Treatment of Postherpetic Neuralgia (PHN) (新闻稿). PRNewswire. 2009-08-24 [2011-06-13]. （原始内容存档于2016-09-21）.
Retigabine NDA accepted for filing (新闻稿). PRNewswire. 2009-12-30 [2010-07-19]. （原始内容存档于2023-10-10）.
Lowry F. Epilepsy drug exogabine gets green light from FDA Advisory Panel. Medscape. 2010-08-12 [2010-08-13]. （原始内容存档于2023-10-10）.
[No authors listed]. August 11, 2010: Peripheral and Central Nervous System Drugs Advisory Committee Meeting Announcement. U.S. Food and Drug Administration. 2010-06-25 [2010-07-19]. （原始内容存档于2017-07-22）.
U.S. Drug Enforcement Administration. Schedules of Controlled Substances: Placement of Ezogabine Into Schedule V (PDF). Federal Register. 15 December 2011, 76 (241) [2023-11-07]. （原始内容存档 (PDF)于2017-06-16）.

瑞替加滨 (Chinese Wikipedia)

archive.org (Global: 6th place; Chinese: 4th place)

doi.org (Global: 2nd place; Chinese: 23rd place)

drugs.com (Global: 399th place; Chinese: 208th place)

epilepsysociety.org.uk (Global: low place; Chinese: low place)

fda.gov (Global: 447th place; Chinese: 581st place)

gpo.gov (Global: 1,360th place; Chinese: 1,262nd place)